Prostaglandin-kallikrein-renin system during acute sulphinpyrazone administration in healthy volunteers.
Sulphinpyrazone administered acutely to 8 healthy male volunteers decreased the urinary (U) excretion of prostaglandin (PG)E2  (p less than 0.01)( but not of PGF2 alpha. Also, the ratio U-PGE2/U-PGF2 alpha and the urinary excretion of kallikrein declined (p less than 0.001 and p less than 0.05 respectively). Sulphinpyrazone therapy caused a significant inhibition of PRA (p less than 0.05). Renal function, as assessed by serum creatinine and creatinine clearance, remained constant in these normal men, possibly related to the fact that both the vasodilatory PG-kallikrein-kinin system and the vasoconstrictive renin-angiotensin system were inhibited by sulphinpyrazone. However, it is conceivable that in clinical situations where vasoconstrictive stimuli are enhanced, sulphinpyrazone can disturb the balance between those systems and can lead to an impaired renal function.
D000328:Adult; D003404:Creatinine / Q000097:blood; D006801:Humans; D007610:Kallikreins / Q000502:physiology*; D008297:Male; D011453:Prostaglandins / Q000502:physiology*; D012083:Renin / Q000502:physiology*; D013442:Sulfinpyrazone / Q000494:pharmacology*; D013997:Time Factors
D011453:Prostaglandins; D003404:Creatinine; D007610:Kallikreins; D012083:Renin; D013442:Sulfinpyrazone